What if

you could be at the forefront of cancer detection

Cancer doesn’t hold back

There’s no training, practice, or test run with cancer. There’s no Let’s get back to that later.”

So patients, understandably, are asking for help today. We all know testing for cancer earlier is often the right thing to do. And now, we have the technology to help take action. Join us, not only in trying to impact lives, but in our shared goal of defining the future of patient-first care.

72% of cancers are not tested for today

In order to provide earlier cancer care to more patients, we need to confront today’s challenge: routine screenings fail to detect 72% of cancers.1 These cancers can go undetected until they have progressed to an advanced stage where outcomes are often poor and treatment costs are high.2 – 5

1 in 3 women and 1 in 2 men will be diagnosed with cancer 1 in 3 women and 1 in 2 men will be diagnosed with cancer

Introducing the Galleri® test

The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.

With the Galleri test, patients could receive the benefits of early detection of multiple cancers through a simple blood draw.

50+ cancer types detected

including cancers not routinely screened for7,8

0.5% false-positive rate

to help minimize unnecessary medical procedures7

89% accuracy

in predicting the location of the cancer, directing diagnostic workup7

The Galleri test is supported by large clinical studies.

The Galleri test is designed to integrate seamlessly to fit your needs

We offer a flexible model that is customized to your needs, including options for full support around marketing campaigns, wraparound clinical support services, and much more. Plus, our simple implementation ensures a positive overall experience:


Test ordered by healthcare provider


Blood draw at provider office or lab


Return of results within 10 business days + support services

The strongest partnerships are based on shared goals

We are experts in implementing complex partnerships and are charged to find inflection points in alignment with your health system’s goals. From improving population health via data analytics and clinical partnerships, to focusing on shared strategies in education and commercialization, we’re built for collaboration.

Contact us to learn more

Let’s discuss how your health system can be on the forefront of early cancer detection.
The Galleri test is only available in the United States.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you

Please check your inbox. You must confirm your subscription to receive emails for the Galleri test.

Important safety information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected” does not rule out cancer. A test result of Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / test information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes. 

  1. Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006 – 2015.
  2. Surveillance, Epidemiology, and End Results (SEER) Program (www​.seer​.can​cer​.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin. Late/​Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
  3. Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
  4. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402 – 10.
  5. DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
  6. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. [updated 2020 Jan 13; cited 2021 Feb 18]. Available from: https://​www​.can​cer​.org/​c​a​n​c​e​r​/​c​a​n​c​e​r​-​b​a​s​i​c​s​/​l​i​f​e​t​i​m​e​-​p​r​o​b​a​b​i​l​i​t​y​-​o​f​-​d​e​v​e​l​o​p​i​n​g​-​o​r​-​d​y​i​n​g​-​f​r​o​m​-​c​a​n​c​e​r​.html
  7. Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
  8. The Galleri test does not detect all cancers and should be used in addition to, and not instead of, routine cancer screening tests recommended by clinical guideline organizations such as the American Cancer Society or the US Preventive Services Task Force (USPSTF).